clinical trial · NCT00650481
Fasting Study of Oxybutynin Chloride Extended-release Tablets 5 mg and Ditropan XL® Tablets 5 mg
HealthyOxybutynin Chloride Extended-release Tablets 5 mgDitropan XL® Tablets 5 mg
brief summary
The objective of this study was to investigate the single-dose relative bioavailability of Mylan's oxybutynin chloride Extended-release tablets to ALZA's Ditropan XL® tablets following a single, oral 20 mg (4 x 5 mg) dose under fasting conditions.
started
Dec 1, 2002
primary completion
Dec 1, 2002
completion
Jan 1, 2003
last updated
Apr 24, 2024
official title
Single-Dose Fasting In Vivo Bioequivalence Study of Oxybutynin Chloride Extended-release Tablets (5 mg; Mylan) and Ditropan XL® Tablets (5 mg; ALZA) in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol